Cargando…

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis

We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target l...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Aya, Moriguchi, Michihisa, Seko, Yuya, Shima, Toshihide, Mitsumoto, Yasuhide, Takashima, Hidetaka, Kimura, Hiroyuki, Fujii, Hideki, Ishikawa, Hiroki, Yo, Takaharu, Ishiba, Hiroshi, Morita, Atsuhiro, Jo, Masayasu, Nagao, Yasuyuki, Arai, Masahiro, Hara, Tasuku, Okajima, Akira, Muramatsu, Akira, Yoshinami, Naomi, Nakajima, Tomoki, Mitsuyoshi, Hironori, Umemura, Atsushi, Nishikawa, Taichiro, Yamaguchi, Kanji, Okanoue, Takeshi, Itoh, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140019/
https://www.ncbi.nlm.nih.gov/pubmed/32209994
http://dx.doi.org/10.3390/cancers12030754
_version_ 1783518900699267072
author Takahashi, Aya
Moriguchi, Michihisa
Seko, Yuya
Shima, Toshihide
Mitsumoto, Yasuhide
Takashima, Hidetaka
Kimura, Hiroyuki
Fujii, Hideki
Ishikawa, Hiroki
Yo, Takaharu
Ishiba, Hiroshi
Morita, Atsuhiro
Jo, Masayasu
Nagao, Yasuyuki
Arai, Masahiro
Hara, Tasuku
Okajima, Akira
Muramatsu, Akira
Yoshinami, Naomi
Nakajima, Tomoki
Mitsuyoshi, Hironori
Umemura, Atsushi
Nishikawa, Taichiro
Yamaguchi, Kanji
Okanoue, Takeshi
Itoh, Yoshito
author_facet Takahashi, Aya
Moriguchi, Michihisa
Seko, Yuya
Shima, Toshihide
Mitsumoto, Yasuhide
Takashima, Hidetaka
Kimura, Hiroyuki
Fujii, Hideki
Ishikawa, Hiroki
Yo, Takaharu
Ishiba, Hiroshi
Morita, Atsuhiro
Jo, Masayasu
Nagao, Yasuyuki
Arai, Masahiro
Hara, Tasuku
Okajima, Akira
Muramatsu, Akira
Yoshinami, Naomi
Nakajima, Tomoki
Mitsuyoshi, Hironori
Umemura, Atsushi
Nishikawa, Taichiro
Yamaguchi, Kanji
Okanoue, Takeshi
Itoh, Yoshito
author_sort Takahashi, Aya
collection PubMed
description We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target lesions’ longest diameters from baseline according to the Response Evaluation Criteria in Solid Tumors (RECIST). The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 5.0 months. The receiver operating characteristic curve analysis in differentiating long-term responders (PFS ≥ 5.0 months) from short-term responders (PFS < 5.0 months) revealed an ETS cut-off value of 10%. ETS ≥ 10% was significantly correlated with better PFS and OS compared with ETS < 10%. Additionally, ETS ≥ 10% showed a better discrimination ability on prognosis compared with modified RECIST-based objective response at the first evaluation. Multivariate analysis confirmed ETS ≥ 10% as an independent predictor of better OS, as well as a Child–Pugh score of 5 and macrovascular invasion. In conclusion, ETS ≥ 10% was strongly associated with outcome in patients treated with LEN. This biomarker could allow earlier assessment of the treatment response and guide treatment decision-making for HCC.
format Online
Article
Text
id pubmed-7140019
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71400192020-04-13 Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis Takahashi, Aya Moriguchi, Michihisa Seko, Yuya Shima, Toshihide Mitsumoto, Yasuhide Takashima, Hidetaka Kimura, Hiroyuki Fujii, Hideki Ishikawa, Hiroki Yo, Takaharu Ishiba, Hiroshi Morita, Atsuhiro Jo, Masayasu Nagao, Yasuyuki Arai, Masahiro Hara, Tasuku Okajima, Akira Muramatsu, Akira Yoshinami, Naomi Nakajima, Tomoki Mitsuyoshi, Hironori Umemura, Atsushi Nishikawa, Taichiro Yamaguchi, Kanji Okanoue, Takeshi Itoh, Yoshito Cancers (Basel) Article We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target lesions’ longest diameters from baseline according to the Response Evaluation Criteria in Solid Tumors (RECIST). The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 5.0 months. The receiver operating characteristic curve analysis in differentiating long-term responders (PFS ≥ 5.0 months) from short-term responders (PFS < 5.0 months) revealed an ETS cut-off value of 10%. ETS ≥ 10% was significantly correlated with better PFS and OS compared with ETS < 10%. Additionally, ETS ≥ 10% showed a better discrimination ability on prognosis compared with modified RECIST-based objective response at the first evaluation. Multivariate analysis confirmed ETS ≥ 10% as an independent predictor of better OS, as well as a Child–Pugh score of 5 and macrovascular invasion. In conclusion, ETS ≥ 10% was strongly associated with outcome in patients treated with LEN. This biomarker could allow earlier assessment of the treatment response and guide treatment decision-making for HCC. MDPI 2020-03-23 /pmc/articles/PMC7140019/ /pubmed/32209994 http://dx.doi.org/10.3390/cancers12030754 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Takahashi, Aya
Moriguchi, Michihisa
Seko, Yuya
Shima, Toshihide
Mitsumoto, Yasuhide
Takashima, Hidetaka
Kimura, Hiroyuki
Fujii, Hideki
Ishikawa, Hiroki
Yo, Takaharu
Ishiba, Hiroshi
Morita, Atsuhiro
Jo, Masayasu
Nagao, Yasuyuki
Arai, Masahiro
Hara, Tasuku
Okajima, Akira
Muramatsu, Akira
Yoshinami, Naomi
Nakajima, Tomoki
Mitsuyoshi, Hironori
Umemura, Atsushi
Nishikawa, Taichiro
Yamaguchi, Kanji
Okanoue, Takeshi
Itoh, Yoshito
Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
title Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
title_full Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
title_fullStr Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
title_full_unstemmed Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
title_short Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
title_sort early tumor shrinkage as a predictive factor for outcomes in hepatocellular carcinoma patients treated with lenvatinib: a multicenter analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140019/
https://www.ncbi.nlm.nih.gov/pubmed/32209994
http://dx.doi.org/10.3390/cancers12030754
work_keys_str_mv AT takahashiaya earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT moriguchimichihisa earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT sekoyuya earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT shimatoshihide earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT mitsumotoyasuhide earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT takashimahidetaka earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT kimurahiroyuki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT fujiihideki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT ishikawahiroki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT yotakaharu earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT ishibahiroshi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT moritaatsuhiro earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT jomasayasu earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT nagaoyasuyuki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT araimasahiro earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT haratasuku earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT okajimaakira earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT muramatsuakira earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT yoshinaminaomi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT nakajimatomoki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT mitsuyoshihironori earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT umemuraatsushi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT nishikawataichiro earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT yamaguchikanji earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT okanouetakeshi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis
AT itohyoshito earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis